Rani Therapeutics (RANI) to Post Quarterly Earnings on Thursday

Rani Therapeutics (NASDAQ:RANI) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Rani Therapeutics to announce earnings of ($0.05) per share and revenue of $0.9250 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $1.71 million during the quarter, compared to analyst estimates of $1.12 million. On average, analysts expect Rani Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Rani Therapeutics Trading Up 3.5%

Shares of NASDAQ:RANI opened at $0.80 on Tuesday. The firm has a market capitalization of $99.27 million, a PE ratio of -1.95 and a beta of 0.78. Rani Therapeutics has a 1-year low of $0.44 and a 1-year high of $3.87. The business’s 50 day moving average is $0.79 and its 200-day moving average is $1.01.

Insiders Place Their Bets

In related news, CEO Talat Imran acquired 35,000 shares of the firm’s stock in a transaction on Friday, July 17th. The shares were bought at an average cost of $0.72 per share, with a total value of $25,200.00. Following the completion of the acquisition, the chief executive officer owned 469,736 shares of the company’s stock, valued at $338,209.92. This trade represents a 8.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 26.73% of the company’s stock.

Hedge Funds Weigh In On Rani Therapeutics

A number of hedge funds have recently modified their holdings of RANI. Virtu Financial LLC acquired a new stake in Rani Therapeutics in the 4th quarter valued at $69,000. OMERS ADMINISTRATION Corp acquired a new position in Rani Therapeutics during the fourth quarter worth $93,000. Farallon Capital Management LLC acquired a new position in Rani Therapeutics during the fourth quarter worth $105,000. Kestra Private Wealth Services LLC lifted its holdings in shares of Rani Therapeutics by 44.8% during the third quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company’s stock valued at $113,000 after acquiring an additional 70,002 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in shares of Rani Therapeutics during the fourth quarter valued at $155,000. 30.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on RANI shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of Rani Therapeutics in a research report on Wednesday, May 20th. Lake Street Capital started coverage on shares of Rani Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings lowered shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Rani Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.